Preliminary results of a study comparing Atmo Biosciences’ novel ingestible gas-sensing capsule with a validated wireless motility capsule indicate that the Atmo capsule is a safe and promising tool to assess gut transit time.

Data from the Monash University comparative study, led by Professor Peter Gibson, was presented in a poster at the Meeting of the Federation of Neurogastroenterology & Motility (FNM 2020), held in Adelaide last week.

Atmo Biosciences is ramping up manufacture of its third generation Atmo Gas Capsule at Planet Innovation’s ISO 13485:2016 certified medtech manufacturing facility.

Our CEO Malcolm Hebblewhite recently chatted with Theresa “Sam” Houghton of The Modern Health Nerd podcast about how Atmo is shining a light on the mysteries of the human gut, and what that could mean for the millions of people who suffer from gut disorders like IBS and IBD.

Listen to the discussion below or search for “The Modern Health Nerd” on Apple Podcasts, Overcast or Spotify.

Atmo Biosciences has been awarded a $620,000 Australian Government grant through the BioMedTech Horizons (BMTH) program.

Atmo Biosciences has raised a further A$2.5 million in an oversubscribed funding round, supplementing an initial seed raise in March 2019.

Seed Health, a microbial sciences company, is partnering with Atmo Biosciences to use its ingestible gas-sensing capsule to study the impact of probiotics on the gut microbiome.

Atmo Biosciences beat 10 other contenders to win the Early Stage Investment Forum (ESIF) at AusBiotech 2019, held at the Melbourne Convention Centre last week.

Former Cochlear Chief Executive Officer Dr. Chris Roberts AO has been appointed as a Non-Executive Director to the Board of Atmo Biosciences, a digital health business commercializing a world-first ingestible gas-sensing capsule for gut health.